Profile data is unavailable for this security.
About the company
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
- Revenue in INR (TTM)66.56m
- Net income in INR-1.61bn
- Incorporated1989
- Employees141.00
- LocationSuven Life Sciences LtdSDE Serene Chambers 6th FloorRoad No. 5 Avenue 7, Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 023541142
- Fax+91 4 023541152
- Websitehttps://www.suven.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clarity Pharmaceuticals Ltd | 0.00 | -2.75bn | 51.32bn | -- | -- | 7.08 | -- | -- | -0.1629 | -0.1629 | 0.00 | 0.397 | 0.00 | -- | -- | -- | -49.89 | -- | -53.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Shanghai Aladdin Biochemical Tech Co Ltd | 6.77bn | 1.27bn | 53.72bn | 652.00 | 43.14 | 4.19 | -- | 7.94 | 0.3127 | 0.3127 | 1.67 | 3.22 | 0.3411 | 0.4437 | 10.06 | 866,966.60 | 7.74 | 7.81 | 8.80 | 8.60 | 61.81 | 60.61 | 22.68 | 24.95 | 2.55 | 47.48 | 0.2789 | 48.33 | 32.44 | 20.55 | 15.07 | 9.17 | 41.61 | -- |
| Beijing Kawin Technol Sha-hld Co Ltd | 14.96bn | 1.75bn | 54.75bn | 600.00 | 30.96 | 2.44 | -- | 3.66 | 0.8642 | 0.8642 | 7.27 | 10.97 | 0.5053 | 1.55 | 3.93 | 2,082,030.00 | 6.46 | 5.55 | 8.05 | 7.14 | 81.90 | 84.98 | 12.79 | 9.40 | 3.94 | -- | 0.1205 | 45.97 | -12.87 | 8.32 | 22.18 | 21.60 | 40.30 | -- |
| Visen Pharmaceuticals | 0.00 | -2.18bn | 55.55bn | 58.00 | -- | 19.00 | -- | -- | -1.77 | -1.77 | 0.00 | 2.35 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | 26.98 | -- | -- | -- |
| Takara Bio Inc | 26.22bn | 606.07m | 57.63bn | 1.78k | 95.08 | 0.857 | 18.37 | 2.20 | 8.65 | 8.65 | 374.03 | 959.19 | 0.3653 | 1.56 | 3.57 | 25,317,030.00 | 0.8816 | 8.66 | 0.9384 | 9.70 | 57.88 | 63.76 | 2.41 | 17.16 | 6.34 | -- | 0.0094 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| Hinova Pharmaceuticals Inc | 4.39m | -2.21bn | 57.98bn | 173.00 | -- | 4.16 | -- | 13,201.54 | -1.86 | -1.86 | 0.0037 | 11.75 | 0.0003 | 1.57 | 0.4509 | 2,120.46 | -13.44 | -26.09 | -14.58 | -29.74 | -101.40 | -- | -50,262.43 | -78,863.60 | 7.49 | -- | 0.0225 | -- | -- | -38.67 | 32.18 | -- | 139.77 | -- |
| Suven Life Sciences Ltd | 66.56m | -1.61bn | 60.33bn | 141.00 | -- | 54.85 | -- | 906.36 | -7.37 | -7.37 | 0.3053 | 5.04 | 0.0317 | -- | 2.72 | -- | -76.53 | -54.10 | -83.92 | -58.12 | -- | -- | -2,415.11 | -1,010.72 | 3.20 | -3,682.30 | 0.00 | -- | -43.08 | -14.32 | -52.98 | -- | 73.29 | -- |
| Bide Pharmatech Co Ltd | 13.60bn | 1.46bn | 66.30bn | 738.00 | 44.42 | 2.63 | -- | 4.88 | 1.37 | 1.37 | 12.77 | 23.19 | 0.4497 | 0.8938 | 4.61 | 1,538,909.00 | 4.83 | 7.02 | 5.87 | 8.29 | 42.07 | 42.16 | 10.75 | 13.13 | 1.52 | -- | 0.1288 | 48.73 | 0.9298 | 34.69 | 7.17 | -- | 80.65 | -- |
| Jiangsu Yahong Meditech Co Ltd | 2.85bn | -4.61bn | 67.77bn | 391.00 | -- | 2.95 | -- | 23.75 | -0.686 | -0.686 | 0.4245 | 3.37 | 0.101 | 11.92 | 5.39 | 609,575.50 | -16.50 | -14.30 | -18.13 | -15.01 | 75.43 | 73.78 | -163.37 | -703.80 | 8.02 | -- | 0.0827 | -- | 1,365.55 | -- | 4.09 | -- | 50.48 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 12.66bn | 1.61bn | 68.05bn | 1.56k | 42.14 | 5.52 | -- | 5.38 | 1.20 | 1.20 | 9.49 | 9.20 | 0.513 | 35.53 | 1.47 | 679,337.60 | 6.19 | 11.39 | 11.22 | 18.82 | 46.81 | 53.31 | 12.07 | 19.66 | 1.62 | 11.40 | 0.3755 | 11.29 | 15.70 | 35.80 | -3.98 | 30.21 | 3.50 | -- |
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 02 Jul 2025 | 58.42k | 0.03% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Jun 2025 | 1.44k | 0.00% |
| Bandhan AMC Ltd.as of 31 May 2025 | 903.00 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Apr 2025 | 764.00 | 0.00% |
